You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

39 Results
Drug
Other Name(s): Trelstar® (Allergan Pharma)
Oct 2014
Drug
Other Name(s): Nolvadex®-D
May 2022
Drug
Other Name(s): Lanvis®
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Sep 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
May 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2021
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2022
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    tamoxifen
Jun 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Jun 2017
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or has not experienced progression while on a lenalidomide-based regimen in a treatment or maintenance setting, according to clinical criteria
ODB - General Benefit
    dexamethasone
May 2022

Pages